相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Clofarabine and high-dose cytosine arabinoside in the treatment of refractory or relapsed acute myeloid leukaemia
Eric Tse et al.
ANNALS OF HEMATOLOGY (2011)
A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study
Shuichi Miyawaki et al.
BLOOD (2011)
Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study
Xavier Thomas et al.
BLOOD (2011)
Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia
Pamela S. Becker et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
Caicun Zhou et al.
LANCET ONCOLOGY (2011)
Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials
David Grimwade et al.
BLOOD (2010)
Prognostic factors and outcomes of adult patients with acute myeloid leukemia after first relapse
Saiko Kurosawa et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Influence of NPM1 and FLT3-ITD status on outcome in relapsed/refractory AML patients receiving salvage therapy including gemtuzumab ozogamicin
P. Chevallier et al.
LEUKEMIA (2010)
Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR.
Makoto Maemondo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission Systematic Review and Meta-analysis of Prospective Clinical Trials
John Koreth et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Two distinct molecular mechanisms underlying cytarabine resistance in human leukemic cells
Jie Cai et al.
CANCER RESEARCH (2008)
Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine:: A Cancer and Leukemia Group B study
Andreas Neubauer et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia
Richard F. Schlenk et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group
Agnieszka Wierzbowska et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2008)
Prognostic significance of blasts in the cerebrospinal fluid without pleiocytosis or a traumatic lumbar puncture in children with acute lymphoblastic leukemia: Experience of the Dutch Childhood Oncology Group
D. Maroeska W. M. te Loo et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Prognostic impact of c-KIT mutations in core binding factor leukemas:: an Italian retrospective study
R Cairoli et al.
BLOOD (2006)
KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival
S Schnittger et al.
BLOOD (2006)
TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer
RS Herbst et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16):: A cancer and leukemia group B study
G Marcucci et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Biochemical modulation of cytarabine triphosphate by clofarabine
T Cooper et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2005)
Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype:: A cancer and leukemia group B study
SS Farag et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22):: Results from CALGB 8461
JC Byrd et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 2
RS Herbst et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia:: A survey of the German Acute Myeloid Leukemia Intergroup
RF Schlenk et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy
VL Damaraju et al.
ONCOGENE (2003)
Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias
RS Care et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia:: results from Cancer and Leukemia Group B (CALGB 8461)
JC Byrd et al.
BLOOD (2002)
Combination regimen of cladribine (2-chlorodeoxyadenosine), cytarabine and G-CSF (CLAG) as induction therapy for patients with relapsed or refractory acute myeloid leukemia
T Robak et al.
LEUKEMIA & LYMPHOMA (2000)
分享论文
